ClinicalTrials.gg
RecruitingNCT06533865Updated Apr 23, 2026

Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea

A Phase 3 interventional study of Romosozumab and Placebo in FHA (Functional Hypothalamic Amenorrhea), sponsored by Massachusetts General Hospital. Recruiting at 2 sites in United States. Open to female participants aged 14 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Massachusetts General Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
14 Years to 30 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.

Planned enrollment
9th of 30
114 · median 37
Started
2025
with 3 others
Phase 3
5 of 43
1 open now
Registered
39th of 43
by date
Lead sponsor
8 of 43
Massachusetts General Hospital

Among the 43 studies in Amenorrhea with a site in United States, this one is the 9th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2025, is one of 5 in phase 3, and was the 39th registered.

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

Browse Amenorrhea studies →

Open to participants now

7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.

This study: 14 Years to 30 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Amenorrhea with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to determine whether romosozumab will improve bone density in girls and women with functional hypothalamic amenorrhea (cessation of the menstrual period due to intense exercise, stress, or an eating disorder) who have low bone density. Participants will be randomly assigned to receive romosozumab or placebo for 6 months. All participants will receive one IV infusion of zoledronate at the 6 month visit. All participants will also receive transdermal estradiol and cyclic progesterone. We will investigate whether participants who receive active romosozumab will demonstrate greater improvements in bone density at one year than those who receive placebo. We will also compare bone density over a year with healthy controls (girls and women of similar age who have regular menstrual periods).

03

Conditions studied

  • FHA (Functional Hypothalamic Amenorrhea)

Browse trials for

04

Who can participate

Ages eligible
14 Years to 30 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For FHA and controls:

  • Female, age 14-30 years, skeletally mature with bone age ≥ 12 years
  • For women of reproductive age, agree to use one of the following for the study duration:

    1. an effective non-hormonal method
    2. a progestin releasing intrauterine device (no evidence of systemic skeletal effects)
    3. a progestin releasing implant
    4. does not have a history of sexual activity that could lead to pregnancy (i.e., same-sex partners only or total abstinence has been and is their preferred lifestyle)
  • Biochemical criteria:
  • Negative βHCG (pregnancy test)
  • TSH within twice the ; potassium, magnesium within the normal range; prolactin \<10 ng/mL above the upper limit of normal; FSH not elevated.
  • Serum ≤ 3 times upper limit of normal, LDL ≤ 190 mg/dl
  • ≥ 30ml/minute
  • If the diagnosis of FHA is unclear, we may check additional labs (e.g., testosterone and sex hormone binding globulin if there is a suspicion of PCOS based on clinical hyperandrogenism).

Additional inclusion criteria for FHA:

  • Less than 3 menses in the preceding 6 months
  • BMD Z-score ≤ -1.0 at ≥ 1 skeletal site (for subjects \<18 years old, we will use the height Z-score-adjusted BMD Z-score using the pediatric bone density calculator developed by the National Institutes of Health and currently maintained by the Children's Hospital of Philadelphia)
  • Dental check-up within the past year
  • If the menstrual status of the subject is unclear due to the presence of a progestin-releasing IUD, serum estradiol levels will be checked twice, at least one week apart. Both estradiol levels must be \< 50 pg/mL.At the discretion of the study clinician, subjects with a diagnosis of PCOS may undergo one to two serum estradiol levels, at least one week apart. The estradiol level(s) must be \< 50 pg/mL

Exclusion criteria

Exclusion Criteria:

For FHA and controls

  • Disease other than FHA known to affect bone, including untreated thyroid dysfunction, Cushing's disease, renal failure, diabetes mellitus
  • Use of bisphosphonates in the past year
  • Use of other medications known to affect bone metabolism within 3 months of the study (other than calcium and vitamin D supplementation).
  • Current use of systemic
  • Migraine with aura as classified in IHS Classification ICHD-3.
  • Personal history of or first-degree relative with unprovoked thromboembolism (unless the subject has been tested and ruled out for a hypercoagulable state).
  • Active substance use disorder; currently smokes or vapes
  • History of or Paget disease of bone
  • Pregnant, planning to become pregnant within 12 months after the end of treatment and/or breastfeeding

Additional exclusion criteria for FHA

  • Cardiovascular: History of myocardial infarction or stroke; history of hypertension or use of anti-hypertensive medications
  • Immunodeficiency or taking therapy
  • Other conditions that can cause oligo-amenorrhea such as PCOS, primary ovarian insufficiency. A participant with PCOS may be included if a study clinician determines that missed menstrual periods are more likely a consequence of FHA.
  • Dental: Osteonecrosis of the jaw (ONJ) or risk factor for ONJ, such as invasive dental procedures (tooth extraction, dental implants, oral surgery in the past 3 months), poor oral hygiene, periodontal and/or pre-existing dental disease
  • Planned invasive dental procedure or other planned major surgery for 18 months after the baseline visit
  • Known sensitivity or absolute to any of the products or components of the medications to be administered (romosozumab, zoledronic acid, transdermal estradiol, micronized progesterone, calcium or vitamin D supplements)
  • Concerning findings for ischemia Additional exclusion criteria for normal-weight healthy controls
  • BMD Z-score \<-2.5 (who we will refer for evaluation)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    Romosozumab

    Participants with functional hypothalamic amenorrhea randomized to romosozumab.

    Drug: Romosozumab · Drug: Zoledronic acid

  • Placebo comparator
    Placebo

    Participants with functional hypothalamic amenorrhea randomized to placebo.

    Drug: Placebo · Drug: Zoledronic acid

  • No intervention
    Healthy Controls

    Healthy controls (girls and women with regular menstrual periods)

Interventions

  • Six monthly subcutaneous injections. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.

    Also known as: Evenity

  • DrugPlacebo

    Identical to romosozumab but inactive. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.

  • One intravenous infusion

    Also known as: Zoledronate, Reclast

06

What researchers measure

Primary outcomes

  1. Lumbar spine bone density

    6-month change in lumbar spine bone density

    Time frame: 0 and 6 months

  2. Tibial cortical thickness

    6-month change in tibial cortical thickness

    Time frame: 0 and 6 months

  3. Tibial failure load

    6-month change in tibial failure load

    Time frame: 0 and 6 months

Secondary outcomes

  1. Femoral neck and total hip bone density

    6- and 12-month change in femoral neck and total hip bone density

    Time frame: 0, 6, and 12 months

  2. Lumbar spine bone density

    12-month change in lumbar spine bone density

    Time frame: 0 and 12 months

  3. Radial cortical thickness

    6- and 12-month change in radial cortical thickness

    Time frame: 0, 6, and 12 months

  4. Tibial cortical thickness

    12-month change in tibial cortical thickness

    Time frame: 0 and 12 months

  5. P1NP and CTX

    1-, 6-, and 12-month change in P1NP and CTX

    Time frame: 0, 1, 6, and 12 months

  6. Radial failure load

    6- and 12-month change in radial failure load

    Time frame: 0, 6, and 12 months

  7. Tibial failure load

    12-month change in change in tibial failure load

    Time frame: 0 and 12 months

  8. Lumbar spine, femoral neck, and total hip bone density

    6- and 12-month in lumbar spine, femoral neck, and total hip bone density

    Time frame: 0, 6, and 12 months

  9. P1NP and CTX

    1-, 6- and 12-month change in markers of bone metabolism

    Time frame: 0, 1, 6 and 12 months

  10. Tibial and radial cortical thickness

    6- and 12-month change in tibial and radial cortical thickness

    Time frame: 0, 6 and 12 months

  11. Tibial and radial failure load

    6- and 12-month change in tibial and radial failure load

    Time frame: 0, 6 and 12 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Oct 2028, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 1, 2024
StartActual
Mar 19, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Apr 2029
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06533865
Responsible party
Karen Klahr Miller, MD (Chief, Neuroendocrine Unit, Massachusetts General Hospital, Massachusetts General Hospital) — Principal investigator
First posted
Aug 1, 2024
Start date
Mar 19, 2025
Primary completion
Oct 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Apr 23, 2026

Study contacts

Karen K Miller, MD
Contact
kkmiller@mgh.harvard.edu
617-726-3870
Melanie Haines, MD
Contact
mshaines@mgh.harvard.edu
617-726-3897

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Romosozumab · Zoledronic Acid

Start the discussion